JP5885255B2 - 罹患組織における遺伝的変異の同定 - Google Patents

罹患組織における遺伝的変異の同定 Download PDF

Info

Publication number
JP5885255B2
JP5885255B2 JP2012526962A JP2012526962A JP5885255B2 JP 5885255 B2 JP5885255 B2 JP 5885255B2 JP 2012526962 A JP2012526962 A JP 2012526962A JP 2012526962 A JP2012526962 A JP 2012526962A JP 5885255 B2 JP5885255 B2 JP 5885255B2
Authority
JP
Japan
Prior art keywords
cells
genetic
gene
variation
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012526962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013502928A5 (https=
JP2013502928A (ja
Inventor
ジェイムズ トムソン，
ジェイムズ トムソン，
ニック セイ，
ニック セイ，
Original Assignee
セルラー ダイナミクス インターナショナル， インコーポレイテッド
セルラー ダイナミクス インターナショナル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルラー ダイナミクス インターナショナル， インコーポレイテッド, セルラー ダイナミクス インターナショナル， インコーポレイテッド filed Critical セルラー ダイナミクス インターナショナル， インコーポレイテッド
Publication of JP2013502928A publication Critical patent/JP2013502928A/ja
Publication of JP2013502928A5 publication Critical patent/JP2013502928A5/ja
Application granted granted Critical
Publication of JP5885255B2 publication Critical patent/JP5885255B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2012526962A 2009-08-28 2010-08-26 罹患組織における遺伝的変異の同定 Active JP5885255B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23790809P 2009-08-28 2009-08-28
US61/237,908 2009-08-28
PCT/US2010/046735 WO2011025852A1 (en) 2009-08-28 2010-08-26 Identifying genetic variation in affected tissues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015227384A Division JP2016028609A (ja) 2009-08-28 2015-11-20 罹患組織における遺伝的変異の同定

Publications (3)

Publication Number Publication Date
JP2013502928A JP2013502928A (ja) 2013-01-31
JP2013502928A5 JP2013502928A5 (https=) 2013-09-19
JP5885255B2 true JP5885255B2 (ja) 2016-03-15

Family

ID=42827374

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012526962A Active JP5885255B2 (ja) 2009-08-28 2010-08-26 罹患組織における遺伝的変異の同定
JP2015227384A Pending JP2016028609A (ja) 2009-08-28 2015-11-20 罹患組織における遺伝的変異の同定

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015227384A Pending JP2016028609A (ja) 2009-08-28 2015-11-20 罹患組織における遺伝的変異の同定

Country Status (6)

Country Link
US (2) US9506114B2 (https=)
EP (1) EP2470673B1 (https=)
JP (2) JP5885255B2 (https=)
CA (1) CA2769862A1 (https=)
ES (1) ES2509567T3 (https=)
WO (1) WO2011025852A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037509T2 (hu) 2011-09-29 2018-09-28 Cellsnap Llc Készítmények és eljárások toxigenicitás meghatározására
KR20150087321A (ko) 2012-11-21 2015-07-29 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소 생물학적 활성의 결정을 위한 수단 및 방법
PL3014267T3 (pl) 2013-06-28 2019-05-31 Merz Pharma Gmbh & Co Kgaa Środki i sposoby określania aktywności biologicznej polipeptydów neurotoksyny w komórkach
AU2015367329B2 (en) 2014-12-19 2021-02-18 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of BoNT/E in cells
TWI704156B (zh) 2015-03-04 2020-09-11 德商曼茲法瑪股份有限公司 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US172079A (en) 1876-01-11 Improvement in grinding-disks
US4863849A (en) * 1985-07-18 1989-09-05 New York Medical College Automatable process for sequencing nucleotide
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
CA2216439A1 (en) 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
US6391622B1 (en) * 1997-04-04 2002-05-21 Caliper Technologies Corp. Closed-loop biochemical analyzers
AU729377B2 (en) 1997-10-23 2001-02-01 Asterias Biotherapeutics, Inc. Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
EP1274865B1 (en) 2000-04-06 2007-02-14 Epigenomics AG Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
WO2004098490A2 (en) 2002-05-17 2004-11-18 Mount Sinai School Of Medicine Of New York University Mesoderm and definitive endoderm cell populations
US20060046258A1 (en) * 2004-02-27 2006-03-02 Lapidus Stanley N Applications of single molecule sequencing
US7452718B2 (en) 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
US20080038820A1 (en) 2004-06-22 2008-02-14 Rudy-Reil Diane E Induction of pluripotent stem cells into mesodermal lineages
AU2005282414C1 (en) 2004-09-08 2011-04-07 Wisconsin Alumni Research Foundation Culturing human embryonic stem cells
WO2006066320A1 (en) 2004-12-22 2006-06-29 Es Cell International Pte Ltd Differentiation of human embryonic stem cells and cardiomyocytes and cardiomyocyte progenitors derived therefrom
US7606580B2 (en) 2005-05-11 2009-10-20 Aol Llc Personalized location information for mobile devices
ES2527444T5 (es) 2007-04-18 2018-05-17 Hadasit Medical Research Services & Development Limited Células del epitelio pigmentario de la retina derivadas de células madre
IL292561A (en) * 2007-10-12 2022-06-01 Astellas Inst For Regenerative Medicine Improved methods of rpe cell production and rpe cell preparations
US20110151447A1 (en) 2007-11-06 2011-06-23 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells
US8669048B2 (en) * 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof

Also Published As

Publication number Publication date
EP2470673A1 (en) 2012-07-04
WO2011025852A1 (en) 2011-03-03
JP2013502928A (ja) 2013-01-31
ES2509567T3 (es) 2014-10-17
CA2769862A1 (en) 2011-03-03
JP2016028609A (ja) 2016-03-03
US9506114B2 (en) 2016-11-29
US20120322670A1 (en) 2012-12-20
EP2470673B1 (en) 2014-07-30

Similar Documents

Publication Publication Date Title
US12378531B2 (en) Use of RNA for reprogramming somatic cells
JP7589983B2 (ja) リプログラミングベクター
JP2016028609A (ja) 罹患組織における遺伝的変異の同定
Cooke et al. Propensity of patient-derived iPSCs for retinal differentiation: implications for autologous cell replacement
Chou et al. Generation of two isogenic human induced pluripotent stem cell lines from a 15 year-old female patient with MERRF syndrome and A8344G mutation of mitochondrial DNA
Ahmad et al. Generation of two induced pluripotent stem cell (iPSC) lines from patients with Duchenne muscular dystrophy (IGIBi006-A and IGIBi008-A) carrying exonic deletions in the dystrophin gene
US12571042B2 (en) Markers specific for pluripotent stem cells, and methods of using the same
Kim et al. Generation of a patient-specific induced pluripotent stem cell line, KSCBi006-A, for osteogenesis imperfecta type I with the COL1A1, c. 3162delT mutation
US20250027155A1 (en) Markers specific for pluripotent stem cells, and methods of using the same
Alcaine Colet Identification and characterization of the molecular pathways regulating the cell cycle-linked pluripotency exit
WO2011124029A1 (zh) 用于鉴定或调控细胞多能性的关键基因、microrna、其它非编码rna或其组合
Thompsone et al. Lab Resource: Single Cell Line-template
Pars Characterization of a DAND5 P. R152h Control-Derived IPS Cell Line to be Used as a Tool for Heart Disease Modeling
Chen Modeling neurodevelopmental disorders Involving genomic imprinting at human chromosome 15q11-Q13 using iPSC and CRISPR/Cas9 Technology
JP2012187047A (ja) 生命機能の異常をもたらす遺伝的変異がある遺伝子座の同定方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151120

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160204

R150 Certificate of patent or registration of utility model

Ref document number: 5885255

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D03

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250